1. Home
  2. JXG vs BMEA Comparison

JXG vs BMEA Comparison

Compare JXG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JX Luxventure Limited

JXG

JX Luxventure Limited

N/A

Current Price

$10.10

Market Cap

98.9M

Sector

N/A

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.26

Market Cap

85.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JXG
BMEA
Founded
N/A
2017
Country
China
United States
Employees
95
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.9M
85.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
JXG
BMEA
Price
$10.10
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
5.1K
942.0K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.87
52 Week High
$11.80
$2.99

Technical Indicators

Market Signals
Indicator
JXG
BMEA
Relative Strength Index (RSI) 75.18 46.78
Support Level $3.57 $1.23
Resistance Level N/A $1.46
Average True Range (ATR) 0.68 0.09
MACD 0.00 0.01
Stochastic Oscillator 72.03 40.79

Price Performance

Historical Comparison
JXG
BMEA

About JXG JX Luxventure Limited

JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: